TRAP™ Degraders

Biohaven’s lead TRAP degrader, BHV-1400, is designed to remove the specific disease-causing protein Gd-IgA1 while leaving healthy antibodies intact, offering a targeted approach to addressing the root cause of IgA nephropathy (IgAN).

Hear Leading Expert, Professor Jonathan Barratt, Ph.D., FRCP, discuss Gd-IgA1, the Current IgAN Treatment Landscape, and BHV-1400.

Injector

TRAP Degraders are administered via subcutaneous or IV injection

bind to circulating disease-causing proteins

and deliver them to ASGPRs on hepatocytes

for internalization and degradation

HEPATOCYTE

Researching the safe and effective treatment of BHV-1400 for patients with IgA Nephropathy (IgAN)

Drug:

BHV-1400

Ages:

18-65

Phase:

1